trifluridine/tipiracil (Lonsurf)

Following a full submission assessed under the orphan equivalent and end of life process

trifluridine/tipiracil (Lonsurf®) is accepted for restricted use within NHSScotland.

Indication under review: As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

SMC restriction: for use as third line treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction
In a phase III, randomised, double-blind study, trifluridine/tipiracil was associated with an improvement in overall survival compared with placebo.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.